PaxVax raises $22M for PhIII trial of cholera vaccine

PaxVax has raised $22 million in venture capital funding to advance development of its oral cholera vaccine, PXVX0200. The investment gives PaxVax the cash to run a 3,000-patient Phase III trial of the product. If successful, PXVX0200 would become the first FDA-approved cholera vaccine for those visiting high-risk regions. Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.